Skip to main content
. 2020 Aug 26;8(2):e001182. doi: 10.1136/jitc-2020-001182

Figure 4.

Figure 4

Indoleamine 2,3 dioxygenase (IDO) inhibition enhances antitumor responses to cyclic diadenyl monophosphate (CDA). (A–F) B6 mice with established Lewis lung carcinoma (LLC) tumors were treated with CDA with or without IDO inhibitors, 1MT (A, B), NLG-919 (C, D) and BMS-986205 (E, F). Tumor volumes (upper panels) and survival (lower panels) were assessed until experimental endpoints. At end points mice were examined to assess tumor clearance or relapse. Data (mean±SEM) were analyzed using two-way analysis of variance with Bonferroni’s multiple comparisons test for each time point (A, C, E) or log-rank test (B, D, F), n=7–9. *P<0.05, **p<0.01, ****p<0.0001 (vs vehicle (Vh)); #p<0.05, ##p<0.01, ####p<0.0001 (vs CDA monotherapy); &&& p<0.001 (vs BMS-986205 monotherapy).